$ADPT

NEUPERT PETER M sold $3.1M of ADPT

NEUPERT PETER M sold 124,690 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $25.15 ($25.10–$25.23, $3.14M total) across 3 trades on 2026-08-17.

Original reporting
SEC EDGAR · NEUPERT PETER M
Published Aug 20, 2026, 12:07 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ADPT
Bearish
medium confidence
Mentioned
$ADPT
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTBearishLow
01

Why it matters

The director's sale represents a $3.1M reduction in holdings, which may be interpreted by the market as a bearish indicator.

02

Market read

Insider sales are closely watched; this filing could influence short-term trading decisions on ADPT.

03

What to watch

Potential upcoming clinical data releases could offset the sale impact.

Relevance 6/10Novelty 8/10Timing: post-market filing on 2026-08-19

Background

Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

$ADPTBearishMedium confidence
Context

Director Peter Neupert sold 124,690 shares for $3.14M on 2026-08-17, disclosed via Form 4.

Expected impact

Modest downside pressure over the next few days.

Evidence & confidence

The sale size is material for a mid-cap biotech and was executed at $25.15 per share, close to recent market price.

Market effects

May raise concerns among biotech investors about insider sentiment.

Limited to US biotech sector.

Minimal global impact.

Counterpoint

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

  • Adaptive Biotechnologies Corp

    US-listed biotech company (ticker ADPT).

  • Peter Neupert

    Director of Adaptive Biotechnologies.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTMed

Adaptive Biotechnologies Corp (ADPT): Results of Operations and Financial Condition

Adaptive Biotechnologies Corp (ADPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results SEATTLE, Jul. 29, 2026 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the gene

$ADPTMedAI 9/10

Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026

Adaptive Biotechnologies (NASDAQ:ADPT) reported Q1 2026 revenue of $70.9 million, up 35% year over year, driven by its MRD business, which generated 95% of revenue and rose 53%. clonoSEQ test volume increased 41% to 32,595. Net loss narrowed to $20.0 million; non-GAAP Adjusted EBITDA loss was $2.5 million. The company raised full-year 2026 MRD revenue guidance to $260–$270 million.